Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India rejects teneligliptin salts patent

This article was originally published in Scrip

Executive Summary

India has rejected Mitsubishi Tanabe's patent application relating to certain salts of teneligliptin, the dipeptidyl peptidase-4 (DPP-4) inhibitor currently in the news after the arrival of a cut-price generic version on the domestic market.

You may also be interested in...



Mitsubishi Takes Teneligliptin Patent Appeal To Indian Court

Japan's Mitsubishi Tanabe has moved a court against Indian patent authorities in a case concerning its patent application relating to certain salts of teneligliptin. The move has set the cat among the pigeons in the Indian market, where cut price versions of the diabetes drug have made strong gains over the recent past, though it's still unclear if the salt patent may have a bearing on these.

Asia Deal Watch: China Grand, ETheRNA Create mRNA Vaccine JV

Plus deals involving LegoChem/Pyxix, Biohaven/Sosei Heptares, Kyowa Kirin/Helsinn, Dr. Reddy’s/Glenmark, Eisai/Wren, KoBioLabs/Kolmar Korea, Y-Biologics/Pierre Fabre, Generex/Chinese consortium.

Precious Cargo: DHL Gears To Deliver COVID-19 Vaccines

A senior executive shares insights around how the global logistics provider is preparing to deliver the upcoming COVID-19 vaccines across the world. While the company has prior experience with the "deep frozen" temperatures needed for some candidates, there will still be specific challenges and complexities involved. 

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134940

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel